The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?
Chapple
Christopher
C
Sheffield Teaching Hospital NHS Trust, Royal Hallamshire Hospital, Sheffield, UK. C.R.Chapple@sheffield.ac.uk
De Ridder
Dirk
D
D000283:Administration, Intravesical; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D004599:Electric Stimulation Therapy / Q000379:methods*; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D008160:Lumbosacral Plexus; D008297:Male; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D009465:Neuromuscular Agents / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic; D053201:Urinary Bladder, Overactive / Q000628:therapy*
D018727:Muscarinic Antagonists; D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A